Beijing Gene+ Completes $28 Million B Round for Genetic Test Services

00:38 EDT 8 Oct 2019 | ChinaBio Today

Beijing Gene+ Technology closed a $28 million B round led by Co-Stone to advance its oncology gene testing services. The company's $30 million A round, completed in 2016, was led by BGI Group, China's largest genetics sequencing company, which also contributed to the B round along with previous investor Green Pine Capital Partners and Volcanics Venture. Founded in 2015 Gene+ offers tests that assess an individual's genetic risk for developing cancer as well as early detection services and precision medicine guidance. More details....

Share this with colleagues:

Original Article: Beijing Gene+ Completes $28 Million B Round for Genetic Test Services


More From BioPortfolio on "Beijing Gene+ Completes $28 Million B Round for Genetic Test Services"

Quick Search

Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...